Phase III Results: Tiotropium Respimat® Is Effective In Symptomatic Asthma Patients Irrespective Of Their Allergic Status

New Phase III data presented for the first time at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS[1]/LABA[2], irrespective of their allergic status... via Health News from Medical News Today Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/02/phase-iii-results-tiotropium-respimat.html